Highlights Camurus AB

Equities

CAMX

SE0007692850

Real-time Estimate Cboe Europe Other stock markets 08:54:50 2024-04-29 am EDT			5-day change	1st Jan Change
490.1 ^SEK	+0.02%		+3.16%	-8.92%

Apr. 17	Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
Apr. 02	Camurus AB Announces Board Resignations	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	Mar. 05	CI
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Camurus AB Provides Earnings Guidance for the Full Year 2024	Feb. 15	CI
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	Feb. 08	CI
Camurus AB Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly	Dec. 21	CI
Camurus to Trade on Nasdaq Stockholm's Large Cap Segment	Dec. 20	MT
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors	Dec. 14	CI
Camurus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Camurus AB Raises Earnings Guidance for the Year 2023	23-10-23	CI
Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn	23-09-05	CI
Camurus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-18	CI
Camurus AB Provides Earnings Outlook for the Year 2023	23-07-18	CI
Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot in Patients with Acromegaly	23-07-17	CI
Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly	23-06-20	CI
Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder	23-05-23	CI
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Camurus AB Provides Earnings Guidance for the Year 2023	23-05-10	CI
Camurus AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-14	CI
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Camurus AB

Equities

CAMX

SE0007692850

Highlights

Filters